Verition Fund Management
MLTX icon

Verition Fund Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

Verition Fund Management’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.03M Buy
+207,102
New +$3.75M 0.02% 753
2025
Q4 		– Sell
-272,768
Closed -$1.96M – 3773
2025
Q3 		$1.96M Buy
272,768
+249,241
+1,059% +$13M 0.01% 2000
2025
Q2 		$1.11M Sell
23,527
-790
-3% -$32.2K ﹤0.01% 2396
2025
Q1 		$950K Buy
+24,317
New +$1.05M ﹤0.01% 2170

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Verition Fund Management's MLTX Position: Q2 2026 in Review

Verition Fund Management opened a new position in MoonLake Immunotherapeutics (MLTX) in Q2 2026: 207,102 shares worth $4.03M. The stake represents 0.02% of the portfolio and ranks #753 among its holdings. This is a return to the name: Verition Fund Management previously reported a position in MLTX as recently as Q3 2025.

Verition Fund Management first reported a position in MLTX in Q1 2025 and has held it in 4 quarters since. 173 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

  • Verition Fund Management held 207,102 shares of MoonLake Immunotherapeutics worth $4.03M as of Q2 2026.
  • MoonLake Immunotherapeutics was a new Verition Fund Management position in Q2 2026.
  • MoonLake Immunotherapeutics made up 0.02% of Verition Fund Management's portfolio in Q2 2026, its #753 holding.
  • Verition Fund Management first reported a position in MoonLake Immunotherapeutics in Q1 2025 and has held it in 4 quarters since.
  • 173 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on Verition Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.